January 2010 Vol XXXIV Issue 1

Previous MonthNext Month


INFLAMMATORY BOWEL DISEASE, SERIES #58

Keep in Mind: Cyclophosphamide as Effective and Safe Therapeutic Option in Severely Active Crohn's Disease

K.J. Schmidt, J. BŁning, H. Lehnert, K. Fellermann

Cyclophosphamide as effective and safe treatment option with rapid acting potential in refractory severe Crohn's disease. Promising data imply a strong need for additional experience of this very encouraging treatment.



NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #81

Propofol-Related Infusion Syndrome

Leigh Ann Mike

Although the exact pathophysiology of PRIS remains to be determined, impaired tissue metabolism caused by propofol infusion appears to be an important mechanism leading to complete cardiovascular collapse. Risk factors for developing PRIS include sepsis, severe cerebral injury, and high propofol doses. Early recognition of the manifestations is the key to managing PRIS.



A SPECIAL ARTICLE

Management of Achalasia in the 21st Century: A Suggested Approach

Donald O. Castell, Jason R. Roberts

Prior to being diagnosed with achalasia, patients are frequently treated empirically for gastroesophageal reflux. The diagnosis is made in patients with a history suggestive of achalasia and confirmed by a combination of esophageal manometry, upper endoscopy, and barium esophagography. There are currently three different treatment modalities availableóbotulinum toxin injection, pneumatic dilation, and Heller myotomy.



A CASE REPORT

Bleeding Bile (Hemobilia): An Obscure Cause of Upper Gastrointestinal Bleeding: Case Report and Review of the Literature

Rana Khan, Bishnu Sapkota, Grigoriy Goldenberg, Mohamed Mansour, Vincent Notar-Francesco, Maurice A. Cerulli

We present this case to remind clinicians that hemobilia is a possible cause of UGIB, especially in patients who present with jaundice, and in patients with biliary stents it can be fatal.



Departments Section


Medical Bulletin Board

Young Investigator Grant for Probiotics Research

Two Grants in the Amount of $50,000 Application Deadline: February 16, 2010



New Study Results Analyzed the Use of KAPIDEXTM (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD

Results Presented at the American College of Gastroenterology 2009 Annual Scientific Meeting San Diego, CA, October 26, 2009